Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...
Europe's booming botanical drug market is expected to reach a whopping USD 1.1 billion by 2031, driven by high cancer rates and a surge in research on...
The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare...
Clinical stage immuno-oncology company Medigene AG (OTCPK:MDGEF) announces the discontinuation of its blood cancer treatment MDG1021's development program, as it looks to focus on the...